We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals
VRTX

1,519 hedge funds and large institutions have $90.8B invested in Vertex Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 143 funds opening new positions, 550 increasing their positions, 617 reducing their positions, and 156 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more call options, than puts

Call options by funds: $846M | Put options by funds: $533M

8% less first-time investments, than exits

New positions opened: 143 | Existing positions closed: 156

3% less funds holding

Funds holding: 1,559 → 1,519 (-40)

3.23% less ownership

Funds ownership: 93.81% → 90.59% (-3.2%)

11% less repeat investments, than reductions

Existing positions increased: 550 | Existing positions reduced: 617

15% less capital invested

Capital invested by funds: $107B → $90.8B (-$16.4B)

56% less funds holding in top 10

Funds holding in top 10: 16 → 7 (-9)

Holders
1,519
Holders Change
-40
Holders Change %
-2.57%
% of All Funds
19.94%
Holding in Top 10
7
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-56.25%
% of All Funds
0.09%
New
143
Increased
550
Reduced
617
Closed
156
Calls
$846M
Puts
$533M
Net Calls
+$313M
Net Calls Change
-$63.9M

Top Buyers

1
Capital International Investors
Capital International Investors
California
+$858M
2
ClearBridge Investments
ClearBridge Investments
New York
+$467M
3
JP Morgan Chase
JP Morgan Chase
New York
+$236M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$218M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$186M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.3B
2
Capital World Investors
Capital World Investors
California
-$1.18B
3
Jennison Associates
Jennison Associates
New York
-$1.13B
4
Edgewood Management
Edgewood Management
Connecticut
-$404M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$326M
Name Holding Trade Value Shares
Change 		Change in
Stake
PWM
1676
Proathlete Wealth Management
Florida
– -$890 -2 Closed
64 65 66 67
68

VRTX Hedge Fund Activity: Q3 2025 in Review

1,519 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2025, worth a combined $90.8B — down 15% from $107B a quarter earlier.

Sellers outnumbered buyers: 156 funds closed out of VRTX and 143 opened new positions — a net loss of 13 holders — while 617 trimmed existing stakes and 550 added.

The largest buyer was Capital International Investors, adding an estimated $858M. The largest seller was Fidelity Investments, cutting an estimated $1.3B.

  • 1,519 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2025, down from 1,559 in Q2 2025.
  • Funds reported $90.8B of Vertex Pharmaceuticals stock for Q3 2025, down 15% quarter-over-quarter.
  • 143 funds opened new Vertex Pharmaceuticals positions in Q3 2025 and 156 closed out, a net change of -13 holders.
  • The largest Vertex Pharmaceuticals buyer in Q3 2025 was Capital International Investors, an estimated $858M added.
  • The largest Vertex Pharmaceuticals seller in Q3 2025 was Fidelity Investments, an estimated $1.3B sold.

Based on aggregated 13F filings for Q3 2025.